Hormonal
Adipose tissue (AT) dysfunction, rather than fat mass alone, is the primary mechanistic link between obesity and adverse health outcomes, explaining why some individuals with obesity remain metabolically healthy while others with normal weight develop obesity-related diseases.
Your health risk from obesity is not just about how much you weigh, but how your fat tissue is functioning. Factors like visceral fat, inflammation, and insulin sensitivity matter more than BMI alone. Focus on metabolic health markers rather than just the scale.
Rather than excess fat accumulation, dysfunction of adipose tissue may represent the mechanistic link between obesity and adverse health outcomes.
Why this rating
Supported by mechanistic studies and comparisons of metabolically healthy vs. unhealthy obesity phenotypes.
Source
An overview of obesity‐related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes
Matthias Blüher · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16263
More from this paper
- Sustained weight loss of 5-10% or greater through negative energy balance interventions (behavioral, pharmacological, or surgical) prevents, reduces, or resolves obesity-related complications such as type 2 diabetes, hypertension, and fatty liver disease.Strong
- Greater magnitude of weight loss (e.g., >10-15%) is required to achieve remission of type 2 diabetes, whereas moderate weight loss (5-10%) is sufficient for prevention or delay.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →